Actionable NSCLC

The vast majority of the vast majority of lung cancer… meaning Non-Small Cell (85% vs. Small Cell), Adenocarcinoma (40% vs. squamous 30%, vs. large cell 15% vs. anything else) has come a long way. We have learned about many of the different mutations and the companies designing products that target them, but there is still a high unmet need. As we know, many patients have none of the known or actionable’ genomic mutations. It’s good to visually see though how many products have so far been approved. If you were to design better products, where would you aim now?